Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Brain Neoplasms 7Breast Neoplasms 5Testicular Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neuroblastoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Leukemia, Myeloid, Accelerated Phase 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Hairy Cell 4Hodgkin Disease 4Carcinoma, Ovarian Epithelial 4Burkitt Lymphoma 4Blast Crisis 4Primary Myelofibrosis 3Neoplasms 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Glioma 3Wilms Tumor 2Teratoma, Testicular 2Teratoma 2Sezary Syndrome 2Seminoma 2

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Glioma × Therapeutics × CNS × Clear all
NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

Massachusetts General Hospital

Phase EARLY_PHASE1 Active not recruiting
16 enrolled
CNS

Glioma

NCT06305910 2024-03-12

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

OX2 Therapeutics

Phase 1 Recruiting
24 enrolled
CNS

Glioma

NCT00360828 2017-03-23

Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
10 enrolled 6 charts
CNS

Astrocytoma, Brain Neoplasms, Glioma, Neurologic Manifestations, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡